Meeting
2022 ASCO Annual Meeting
Characterizing the genomic landscape of PIK3CA alterations from 121,221 adult patients with cancer: The next tissue-agnostic target?
Authors
Niamh Coleman
The University of Texas MD Anderson Cancer Center, Houston
Niamh Coleman , Jason Roszik , Neha K. Reddy , Vivek Subbiah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3088)
DOI
10.1200/JCO.2022.40.16_suppl.3088
Abstract #
3088
Poster Bd #
80
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Targeting rare variants of a pan-cancer target: The landscape of BRAF non-v600 mutations and BRAF fusions from 172,005 adult patients with cancer.
First Author: Niamh Coleman
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Genomic landscape of acquired resistance to targeted therapies in metastatic colorectal cancer (mCRC).
First Author: Emily Harrold
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor) combination in preclinical colorectal cancer models.
First Author: Razia Aslam
Poster
2020 Gastrointestinal Cancers Symposium
Genomic alterations in colitis-associated cancers in comparison to those found in sporadic colorectal cancer and present in precancerous dysplasia.
First Author: Walid Khaled Chatila